Kakkar is a biotech entrepreneur and physician-scientist, most recently serving as a founding executive at Corvidia Therapeutics.
He joins Pandion as the company advances to the development stage and is nearing the clinic with its first antibody candidates.
Kakkar succeeds Anthony J. Coyle, PhD, who is a founder of Pandion, led the company through its early stage, series A funding and development of its R and D strategy, and will be leaving the company in the transition.
Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment, while avoiding the systemic immunosuppression of conventional medicines.
The company's proprietary technology platform enables the design of bispecific antibodies with targeting fragments that bind to specific tissues at the local site of inflammatory disease, coupled with effector molecules that modulate immune activity to restore immune homeostasis.
With its robust antibody platform, Pandion is developing a pipeline for autoimmune and inflammatory diseases and transplantation, with an initial focus on diseases of the gastrointestinal tract, liver, kidney, pancreas, and skin.
Pandion was founded in 2017 and is funded by a strong syndicate of venture investors. The company is headquartered in Cambridge, Massachusetts.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer